Argument: Some non-stem cell treatment approaches have been growing rapidly, which may reduce the marginal benefit stem cells provide
Supporting examples and quotations
- Alzheimer's - Non-stem-cell treatment methods are growing rapidly, possibly lowering the net benefit from stem cells to treating this disease: US Dep. of Health and Human Services - "NIA [National Institute of Health] is currently supporting 25 AD clinical trials, including large-scale prevention trials, which are testing agents such as hormones, anti-inflammatory drugs, statins, homocysteine-lowering vitamins, and anti-oxidants for their effects on slowing progress of the disease, delaying AD's onset, or preventing the disease altogether. Other intervention trials are assessing the effects of various compounds on the behavioral symptoms (agitation, aggression, and sleep disorders) of people with AD. As imaging and laboratory studies reveal more about AD's pathology, we are identifying a number of novel molecular characteristics that may prove to be targets for future treatment of the disease."
- Diabetes - US DHHS - "Preventing diabetes is the key to controlling the growing diabetes epidemic". This may reduce the net value of stem cell treatment methods: The US DHHS points out that 90 to 95 of the 20 million Americans with diabetes have type 2 (formerly called "adult onset") diabetes, which is preventable. More than 80% of people with type 2 diabetes are overweight or obese. It is for this reason that DHHS prioritizes prevention over treatment options approached by stem cell research. This is also the logic behind a program developed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Centers for Disease Control and Prevention (CDC) entitled: "Small Steps. Big Rewards: Prevent Type 2 Diabetes."